In preclinical models, simultaneous inhibition of LAG-3 and PD-1 showed synergistic antitumor activity. This phase 2-3 study evaluated the combination of relatlimab (anti LAG-3) and nivolumab […]
Axicabtagene ciloleucel is an autologous anti-CD19 CAR T cell therapy indicated for the treatment of Relapsed/Refractory (R/R) large B-cell lymphoma and follicular lymphoma (FL), both after […]
A pooled ACCENT/IDEA analysis demonstrates that for patients with stage III colorectal cancer treated with 6 months of oxaliplatin-based adjuvant chemotherapy, discontinuation of oxaliplatin while maintaining […]
Cancer hallmarks are a tool for understanding the vast complexity of cancer phenotypes and genotypes. As knowledge of cancer mechanisms has progressed, other facets of the […]
The phase 3 study, KEYNOTE-394, demonstrated significant benefit of using pembrolizumab in combination with best supportive care for Asian patients with advanced hepatocellular carcinoma (HCC) in […]
Although the primary endpoint of this phase 2 study was not met, the addition of nivolumab to the standard first-line treatment for metastatic colorectal cancer showed […]
Clinical trial EMPOWER-Cervical 1 demonstrates an overall survival benefit of using cemiplimab as monotherapy, compared with chemotherapy of investigator’s choice, for patients with recurrent or metastatic […]
There was a small increase in pCR initially (with no continuity after surgery), questioning the need to maintain immunotherapy as adjuvant treatment, according to data presented in ASCO 2021 During ASCO World Congress […]
Nivolumab demonstrated superior overall survival versus chemotherapy in patients with previously treated esophageal squamous cell carcinoma, according to ATTRACTION-3 data. At ASCO 2021, immunotherapy efficacy data were released in the first–line setting of Checkmate […]